Gina Tomaine

News

Transplantation Added to RVD Yields Longer PFS Than RVD Alone in Patients With MM

07/18/2022

Among adults with MM, treatment with lenalidomide, bortezomib, and dexamethasone (RVD) and autologous stem-cell transplantation was associated with longer PFS than RVD alone, according to a phase 3 trial.

Among adults with MM, treatment...

07/18/2022

Oncology

News

09/07/2023

Gina Tomaine ;

The rituximab biosimilar, SDZ-RTX, combined with a CHOP regimen was effective and well-tolerated as a frontline treatment for patients with diffuse large B-cell lymphoma (DLBCL), according to a real-world study.

The rituximab biosimilar,...

09/07/2023

Oncology

News

Brexucabtagene Autoleucel Yields Durable Long-term Responses in MCL: 3-Year Follow-up From ZUMA-2

08/02/2022

Gina Tomaine ;

Brexucabtagene autoleucel induced durable long-term responses with manageable safety in patients with relapsed/refractory MCL, according to a 3-year follow-up analysis of the ZUMA-2 study.

Brexucabtagene autoleucel...

08/02/2022

Oncology

News

Momelotinib Superior to Danazol in Symptomatic and Anemic Myelofibrosis Patients Previously Treated With JAK Inhibitor

11/17/2022

Gina Tomaine ;

Momelotinib improved symptom responses, transfusion requirements, and spleen responses for symptomatic and anemic myelofibrosis patients previously treated with a JAK inhibitor when compared with danazol, according to the phase 3 MOMENTUM...

Momelotinib improved symptom...

11/17/2022

Oncology

News

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

04/24/2023

Gina Tomaine ;

On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval was based on the SEQUOIA and ALPINE trials, respectively. The...

On January 19, 2023, the Food...

04/24/2023

Journal of Clinical Pathways

News

Targeted Therapy Combinations Feasible Before Chemoimmunotherapy for Newly Diagnosed DLBCL: Smart Start Trial

09/02/2022

Gina Tomaine ;

Rituximab plus lenalidomide and ibrutinib demonstrated significant clinical activity, manageable safety, and promising survival outcomes both alone and in combination with chemotherapy as a frontline treatment for newly diagnosed DLBCL in the...

Rituximab plus lenalidomide and...

09/02/2022

Oncology

EZH2 Mutation Status at Diagnosis is a Useful Biomarker to Guide First-Line Therapy in Follicular Lymphoma

09/23/2022

Gina Tomaine ;

Study findings show EZH2 mutation status could be a useful biomarker to guide first-line therapy in follicular lymphoma and that ctDNA is a promising tool for identifying patients with this mutation.

Study findings show EZH2...

09/23/2022

Oncology

News

Teclistamab Induces Deep and Durable Responses in Triple–Class-Exposed Relapsed/Refractory MM

07/13/2022

Gina Tomaine ;

Teclistamab, a T-cell–redirecting bispecific antibody, showed promising efficacy in treating patients with triple-class–exposed relapsed or refractory MM, inducing deep and durable responses in a recent study.

Teclistamab, a...

07/13/2022

Oncology

News

FDA Grants Expedited Approval to Quizartinib for Patients With Newly Diagnosed AML With FLT3/ITD Mutations

07/24/2023

Gina Tomaine ;

The FDA granted approval to quizartinib for patients with newly diagnosed FLT3/ITD-positive acute myeloid leukemia, as detected by an FDA-approved test.

The FDA granted approval to...

07/24/2023

Oncology

News

Ibrutinib Plus Bendamustine and Rituximab Prolongs PFS in Older Patients with MCL

08/02/2022

Gina Tomaine ;

Ibrutinib added to bendamustine and rituximab followed by rituximab maintenance yields significantly longer PFS vs placebo in older patients with previously untreated MCL, according to findings from the phase 3 SHINE trial.

Ibrutinib added to bendamustine...

08/02/2022

Oncology